Clinical Trials Logo
  1. Home
  2. Dysfunctional Uterine Bleeding
  3. NCT04428684

COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg

Dysfunctional Uterine Bleeding Clinical Trial

Official title:
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg IN PATIENTS WITH DYSFUNCTIONAL UTERINE BLEEDING REQUIRING ENDOMETRIAL ABLATION.

Clinical Trial Summary

The comparator drug (Zoladex 3.6 mg) is approved for use as a thinning agent for the endometrium prior to endometrial ablation. The dosing recommendation is one or two depots with each depot given four weeks apart. When two depots are administered, surgery should be performed within two to four weeks following administration of the second depot.

Clinical Trial Description

The primary objective of the study is to demonstrate non-inferiority of a generic formulation of goserelin 3.6 mg as compared to Zoladex ® 3.6 mg on endometrial thinning prior to surgery. The study is an open label, multicenter, prospective, parallel group randomized study.

Blind for Sponsor, ultrasound assessment, testing labs and statistician, the study will be performed in premenopausal women with dysfunctional uterine bleeding (DUB) eligible for endometrial ablation. Patients will be randomized in a 1 to 1 ratio to receive either the Peptigroupe test product (Pepti 3.6 mg) or Zoladex® 3.6 mg for a treatment of 8 weeks (two injections).

Ultrasonic measurement of endometrial thickness will be performed on screening and on days 0 (pre-injection), 28 (pre-injection) and 42 (pre surgical procedure).

The pharmacodynamics profile will be tabulated at the end of the study on the basis of the following data:

1. Estradiol

2. LH and FSH as additional information on hormone response

Goserelin safety profile will be assessed throughout the study on the basis of the following assessments:

1. Treatment-emergent AEs

2. Physical examinations

3. Vital signs

4. 12-Lead ECG

5. Laboratory parameters (i.e., biochemistry, haematology, and urinalysis) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04428684
Study type Interventional
Source Peptigroupe Inc.
Contact
Status Completed
Phase Phase 1
Start date October 29, 2018
Completion date June 7, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT04528108 - Chinese Medicine Periodic Therapy for Dysfunctional Uterine Bleeding During Adolescence With Yin Deficiency and Blood Heat Syndrome Phase 2
Recruiting NCT00549159 - CavatermTM vs TCRE in Women With DUB Phase 4
Not yet recruiting NCT04579965 - Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele N/A
Terminated NCT01581905 - Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution N/A
Completed NCT02326922 - The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding Phase 1/Phase 2
Recruiting NCT04396483 - Dysfunctional Uterine Bleeding After Tubal Sterilization N/A
Completed NCT01628432 - Effect of Salpingectomy During Conservative Hysterectomy N/A
Terminated NCT01776203 - Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist Phase 4
Completed NCT01148420 - DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding Phase 4
Completed NCT01173965 - Endometrial Ablation With Non-hysteroscopic Methods Phase 4
Active, not recruiting NCT02103764 - Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB Phase 3
Not yet recruiting NCT04290013 - Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature . Phase 3